Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study.
Fiche publication
Date publication
janvier 2024
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Dr VUITTON Lucine
Tous les auteurs :
Hupé M, Streichenberger A, Wils P, Arab N, Serrero M, Amiot A, Bozon A, Vuitton L, Fumery M, Altwegg R, Nachury M, Hébuterne X, Yzet C, Coban D, Dodel M, Bazoge M, Pereira B, Buisson A
Lien Pubmed
Résumé
Data on infliximab efficacy in bio-exposed patients with ulcerative colitis (UC) are limited.
Mots clés
Bio-exposed patients, Inflammatory bowel disease, Infliximab, Real-world data, Second-line treatment, Ulcerative colitis
Référence
Dig Liver Dis. 2024 01 27;: